HAEMONETICS CORP — Form 10-Q
Filed August 6, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
This 10-Q filing comprises standard executive compensation exhibits: two form Performance Share Unit Award Agreements under Haemonetics' 2019 Long-Term Incentive Compensation Plan (Exhibits 10.1 and 10.2) with templated terms for grant dates, vesting conditions, and change-of-control provisions; and officer certifications (Exhibits 31.1, 31.2, 32.1, 32.2) from CEO Christopher A. Simon and CFO James C. D'Arecca dated August 6, 2026. No specific share counts, dollar amounts, grantees, or performance metrics are disclosed—critical terms are left blank in the template documents.
Why this rating
Routine regulatory filing of stock plan forms and officer certs. No transaction, no dollar impact, no business change. Boilerplate.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.